Gilde Healthcare leads $24 million financing round of respiratory care provider Vapotherm - Gilde Healthcare

Gilde Healthcare leads $24 million financing round of respiratory care provider Vapotherm

April 7, 2014

EXETER, New Hampshire – Vapotherm, Inc. announced a $24MM financing round led by Gilde Healthcare. Adage Capital Management joined as new co-investor. The round was completed by existing investors Morgenthaler Ventures, Kaiser Permanente, 3×5 Special Opportunity Fund, Integral Capital Partners, QuestMark Partners and Cross Creek Capital.

Geoff Pardo, Partner of Gilde Healthcare joins as new member of the Board of Directors:

“Vapotherm’s unique respiratory solution has proven to generate superior patient outcomes and lower the cost of care for providers. We look forward to grow the company internationally and improve healthcare for patients world-wide.”

Vapotherm develops, manufactures and markets advanced respiratory care devices. The company sells innovative, comfortable, noninvasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 600,000 patients have been treated with Vapotherm’s proprietary high flow therapy. For more information, visit www.vtherm.com.

 

About Gilde Healthcare (www.gildehealthcare.com)

Gilde Healthcare (Utrecht, The Netherlands and Cambridge, Massachusetts) is a transatlantic growth capital investor focused on private healthcare companies. It has over €450 million ($600 million) under management and is actively looking to lead new investments in therapeutics, diagnostics, medical devices and healthcare services. For a list of Gilde’s portfolio companies please visit our new website at www.gildehealthcare.com.

Gilde Healthcare company SpliceBio secures $135 Million financing to advance SB-007 in Stargardt disease and expand pipeline

Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as Gilde Healthcare and other existing investors  Proceeds will support clinical development of lead program SB-007...
June 11, 2025

Gilde Healthcare participates in $75 Million Series D round of SpyGlass Pharma to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients

SpyGlass Pharma, a privately-held ophthalmic biotechnology company, announced the closing of a $75 million Series D financing round. SpyGlass’ Drug Delivery Platform aims to provide multiple years of medical therapy, addressing the need for long-term...
June 3, 2025

Gilde Healthcare company Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield

Mainstay Medical Holdings plc today announced that Anthem Blue Cross and Blue Shield (“Anthem”) has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. ReActiv8...
April 28, 2025